{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:01:13Z","timestamp":1794265273599,"version":"4.9.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100021204","name":"California State Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010993","name":"Irish Nephrology Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1053\/j.ajkd.2025.07.023","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:06:13Z","timestamp":1766189173000},"page":"412-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Complement Inhibition in Immunoglobulin A Nephropathy: A Mini-Review"],"prefix":"10.1053","volume":"87","author":[{"given":"Jia Wei","family":"Teh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Stoneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-1308","authenticated-orcid":false,"given":"Michelle M.","family":"O\u2019Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ajkd.2025.07.023_bib1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2025.07.023_bib2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.07.023_bib3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.07.023_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.kint.2022.02.042","article-title":"Application of the international IgA nephropathy prediction tool one or two years post-biopsy","volume":"102","author":"Barbour","year":"2022","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2025.07.023_bib5","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.07.023_bib6","first-page":"629","article-title":"IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1","volume":"118","author":"Suzuki","year":"2008","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1053\/j.ajkd.2025.07.023_bib7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ndt\/gfaa264","article-title":"High levels of gut-homing immunoglobulin A+B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients","volume":"36","author":"Sallustio","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1053\/j.ajkd.2025.07.023_bib8","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.ekir.2025.04.016","article-title":"Carboxymethyl-lysine is a prominent target of circulating IgA in IgA nephropathy","volume":"10","author":"Alibrandi","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2025.07.023_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI5535","article-title":"Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies","volume":"104","author":"Tomana","year":"1999","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.ajkd.2025.07.023_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4049\/jimmunol.1302249","article-title":"The combined role of galactose-deficient IgA1 and streptococcal IgA\u2013binding M protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy","volume":"193","author":"Schmitt","year":"2014","journal-title":"J Immunol"},{"issue":"10 suppl","key":"10.1053\/j.ajkd.2025.07.023_bib11","article-title":"Complement C3 contributes to the pathogenicity of galactose-deficient IgA1-containing immune complexes in IgA nephropathy: FR-PO809 [abstract]","volume":"35","author":"Hall","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.07.023_bib12","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfac204","article-title":"Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries","volume":"37","author":"Makita","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2025.07.023_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ndt\/gfn441","article-title":"Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy","volume":"24","author":"Lai","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2025.07.023_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jcp.21129","article-title":"Complement 3 is involved in changing the phenotype of human glomerular mesangial cells","volume":"213","author":"Wan","year":"2007","journal-title":"J Cell Physiol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.07.023_bib15","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/modpathol.2010.110","article-title":"Podocyte number predicts progression of proteinuria in IgA nephropathy","volume":"23","author":"Xu","year":"2010","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.07.023_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.173651","article-title":"Cross-species single-cell analysis uncovers the immunopathological mechanisms associated with IgA nephropathy progression","volume":"9","author":"Chen","year":"2024","journal-title":"JCI Insight"},{"issue":"12","key":"10.1053\/j.ajkd.2025.07.023_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add6734","article-title":"Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy","volume":"9","author":"Nihei","year":"2023","journal-title":"Sci Adv"},{"issue":"1","key":"10.1053\/j.ajkd.2025.07.023_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2009","journal-title":"Cell Res"},{"issue":"6","key":"10.1053\/j.ajkd.2025.07.023_bib19","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.07.023_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108331","article-title":"Predictive value of mesangial C3 and C4d deposition in IgA nephropathy","volume":"211","author":"Nam","year":"2020","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.07.023_bib21","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1038\/s41598-021-84715-7","article-title":"A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy","volume":"11","author":"Tan","year":"2021","journal-title":"Sci Rep"},{"key":"10.1053\/j.ajkd.2025.07.023_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.638309","article-title":"Alternative complement pathway is activated and associated with galactose-deficient IgA1 antibody in IgA nephropathy patients","volume":"12","author":"Chiu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1053\/j.ajkd.2025.07.023_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molimm.2019.07.017","article-title":"The role of complement in IgA nephropathy","volume":"114","author":"Tortajada","year":"2019","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.07.023_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s12882-024-03832-3","article-title":"The prognostic role of activation of the complement pathways in the progression of advanced IgA nephropathy to end-stage renal disease","volume":"25","author":"Wang","year":"2024","journal-title":"BMC Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.07.023_bib25","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.xkme.2021.06.009","article-title":"Glomerular C4d deposition and kidney disease progression in IgA nephropathy: a systematic review and meta-analysis","volume":"3","author":"Jiang","year":"2021","journal-title":"Kidney Med"},{"issue":"5","key":"10.1053\/j.ajkd.2025.07.023_bib26","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1159\/000502579","article-title":"Clinical significance of galactose-deficient IgA1 by KM55 in patients with IgA nephropathy","volume":"44","author":"Zhang","year":"2019","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"10.1053\/j.ajkd.2025.07.023_bib27","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/ki.1997.171","article-title":"Activated complement C3: a potentially novel predictor of progressive IgA nephropathy","volume":"51","author":"Zwirner","year":"1997","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2025.07.023_bib28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2169\/internalmedicine.43.1023","article-title":"Relationship between serum IgA\/C3 ratio and progression of IgA nephropathy","volume":"43","author":"Komatsu","year":"2004","journal-title":"Intern Med"},{"issue":"4","key":"10.1053\/j.ajkd.2025.07.023_bib29","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","article-title":"Circulating complement factor H\u2013related proteins 1 and 5 correlate with disease activity in IgA nephropathy","volume":"92","author":"Medjeral-Thomas","year":"2017","journal-title":"Kidney Int"},{"issue":"11","key":"10.1053\/j.ajkd.2025.07.023_bib30","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1681\/ASN.2017010076","article-title":"Mannose-binding lectin levels could predict prognosis in IgA nephropathy","volume":"28","author":"Guo","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.07.023_bib31","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ekir.2017.11.015","article-title":"Progressive IgA nephropathy is associated with low circulating mannan-binding lectin\u2013associated serine protease-3 (MASP-3) and increased glomerular factor H\u2013related protein-5 (FHR5) deposition","volume":"3","author":"Medjeral-Thomas","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.ajkd.2025.07.023_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"issue":"7","key":"10.1053\/j.ajkd.2025.07.023_bib33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"issue":"3","key":"10.1053\/j.ajkd.2025.07.023_bib34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molimm.2013.06.001","article-title":"Complement factor H related proteins (CFHRs)","volume":"56","author":"Skerka","year":"2013","journal-title":"Mol Immunol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.07.023_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.07.023_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2025.07.023_bib37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.07.023_bib38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy","volume":"36","author":"Lafayette","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.07.023_bib39","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.ajt.2023.05.031","article-title":"Eculizumab as a therapeutic approach for severe crescentic recurrence of immunoglobulin A nephropathy after kidney transplantation","volume":"23","author":"Duval","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2025.07.023_bib40","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2025.07.023","article-title":"Complement inhibition in immunoglobulin A nephropathy: a mini-review","author":"Teh","year":"2026","journal-title":"Am J Kidney Dis"},{"issue":"10405","key":"10.1053\/j.ajkd.2025.07.023_bib41","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2025.07.023_bib42","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2025.07.023_bib43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.07.023_bib44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"issue":"10 suppl","key":"10.1053\/j.ajkd.2025.07.023_bib45","article-title":"Phase II results of an investigational RNA therapeutic to complement factor B, IONIS-FB-LRx, for treatment of IgA nephropathy: TH-PO1205","volume":"35","author":"Barbour","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.07.023_bib46","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2025.07.023_bib47","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1053\/j.ajkd.2025.07.023_bib48","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy\u2014an open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin Kidney J"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625012119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625012119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T12:05:35Z","timestamp":1774008335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625012119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0272638625012119"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.07.023","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement Inhibition in Immunoglobulin A Nephropathy: A Mini-Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}